i-SENS strengthens position in European CGM insurance and bidding market

i-SENS announced on Monday that its continuous glucose monitor (CGM), CareSens Air, has been listed on new public insurance plans in Poland and the Czech Republic, and has also secured bids in tenders for major hospitals and testing institutions in Finland.

With this, CareSens Air has now completed insurance listings in six countries, including Korea, the U.K., Estonia, and Hungary. In Poland, the adult diabetes population is estimated at approximately 3.1 million, with about 130,000 of these being type 1 diabetes patients. For adult patients, 70 percent of the CGM cost is covered by the government (National Health Fund), with the patient bearing the remaining 30 percent.

Insurance coverage was also finalized in the Czech Republic in this quarter. According to the International Diabetes Federation (IDF), there are approximately 760,000 adult diabetes patients in the Czech Republic, including about 33,000 with type 1 diabetes. The Czech Republic has implemented a system since 2019 that fully reimburses CGM costs for patients with type 1 diabetes.

i-SENS recorded sales of 6.7 billion won ($4.8 million) in the first half of this year alone, surpassing its full-year sales from the previous year (6.2 billion won).

“This insurance listing and tender success mark a significant milestone, accelerating the expansion of our global CGM business,” an i-SENS official said. “We will continue to broaden accessibility in key markets, including Europe, and contribute to improving patients' treatment environments.”